DK177286A - Viruskappeprotein - Google Patents

Viruskappeprotein Download PDF

Info

Publication number
DK177286A
DK177286A DK177286A DK177286A DK177286A DK 177286 A DK177286 A DK 177286A DK 177286 A DK177286 A DK 177286A DK 177286 A DK177286 A DK 177286A DK 177286 A DK177286 A DK 177286A
Authority
DK
Denmark
Prior art keywords
aids
envelope protein
virus envelope
hxb
arv
Prior art date
Application number
DK177286A
Other languages
English (en)
Other versions
DK177286D0 (da
DK171119B1 (da
Inventor
Robert Mitchell Crowl
Robert Charles Gallo
Eragam Premkumar Reddy
George Meade Shaw
Flossie Yeaching Wong-Staal
Original Assignee
Hoffmann La Roche
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24912812&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK177286(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Us Health filed Critical Hoffmann La Roche
Publication of DK177286D0 publication Critical patent/DK177286D0/da
Publication of DK177286A publication Critical patent/DK177286A/da
Application granted granted Critical
Publication of DK171119B1 publication Critical patent/DK171119B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

FIGURE 1 1 ATTCTGCAACAACTGCTGTTTATCCATTTTCAGAATTGGGTGTCGACATAGCAGAATAGGCGTTACTCG . 69 70 ACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGC 138 139 CTAAAACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCATAACAA '207 206 AAGCCTTAGGCATCTCCTATGGCAGGAAGAAGCGGAGACAGGGACGAAGACCTCCTCAAGGCAGTCAGA 276 277 CTCATCAAGTTTCTCTATCAAAGCAGTAAGTAATACATGTAATGCAACCTATACAAATAGCAATAGTAG 345 346 CATTAGTAGTAGCAATAATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATAT 414 415 TAAGACAAAGAAAAATAGACAGGTTAATTGATAGACTAATAGAAAGAGCAGAAGACAGTGGCAATGAGA 483 484 GTGAAGGAGAAATATCAGCACTTGTGGAGATGGGGGTGGAGATGGGGCACCATGCTCCTTGGGATGTTG 552 553 ATGATCTGTAGTGCTACAGAAAAATTGTGGGTCACAGTCTATTATGGGGTACCTGIGTGGAAGGAAGCA 621 622 ACCACCACTCTATTTTGTGCATCAGATGCrAAAGCATATGATACAGAGGTACATAATGTTTGGGCCACA 690 691 CATGCCTGTGTACCCACAGACCCCAACCCACAAGAAGTAGTATTGGTAAATGTGACAGAAAATTTTAAC 759 760 ATGTGGAAAAATGACATGGTAGAACAGATGCATGAGGATATAATCAGTTTATGGGATCAAAGCCTAAAG 828 829 CCATGTGTAAAATTAACCCCACTCTGTGTTAGTTTAAAGTGCACTGATTTGAAGAATGATACTAATACC 897 898 AATAGTAGTAGCGGGAGAATGATAATGGAGAAAGGAGAGATAAAAAACTGCTCTTTCAATATCAGCACA 966 967 AGCATAAGAGGTAAGGTGCAGAAAGAATATGCATTTTTTTATAAACTTGATATAATACCAATAGATAAT 1035 1036 GATACTACCAGCTATACGTTGACAAGTTGTAACACCTCAGTCATTACACAGGCCTGTCCAAAGGTATCC 1104 1105 TTTGAGCCAATTCCCATACATTATTGTGCCCCGGCTGGTTTTGCGATTCTAAAATGTAATAATAAGACG 1173 1174 TTCAATGGAACAGGACCATGTACAAATGTCAGCACAGTACAATGTACACATGGAATTAGGCCAGTAGTA 1242 1243 TCAACTCAACTGCTGTTAAATGGCAGTCTAGCAGAAGAAGAGGTAGTAATTAGATCIGTCAATTTCACG 1311 1312 GACAATGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATTGTACAAGACCCAACAAC 1380 1381 AATACAAGAAAAAAAATCCGTATCCAGAGGGGACCAGGGAGAGCATTTGTTACAATAGGAAAAATAGGA 1449 1450 AATATGAGACAAGCACATTGTAACATTAGIAGAGCAAAATGGAAIGCCACTTTAAAACAGATAGCTAGC 1518 1519 AAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAA 1587 1588 ATTGTAACGCACAGTTTTAATTGTGGAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGT 1656 1657 ACTTGGTTTAATAGTACTTGGAGTACTGAAGGGTCAAATAACACTGAAGGAAGTGACACAATCACACTC 1725 1726 CCATGCAGAATAAAACAATTTATAAACATGTGGCAGGAAGTAGGAAAAGCAATGTATGCCCCTCCCATC 1794 1795 AGCGGACAAATTAGATGTTCATCAAATATTACAGGGCTGCTATTAACAAGAGATGGTGGTAATAACAAC 1863 1864 AATGGGTCCGAGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAA 1932 1933 TATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGA 2001 2002 GAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGC 2070 2071 GCAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAAT 2139 2140 TTGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACrCACAGTCTGGGGCATCAAGCAGCTCCAG 2206 2209 GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCrGGA 2277 2278 AAACTAATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG 2346 2347 AATCACACGACGTGGATGGAGTGGGACAGAGAAATTAACAATTACACAAGCTTAATACACTCCTTAATT 2415 >416 GAAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTrrG 2484 >485 TGGAATTGGTTTAACATAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTTG 2553 >554 GTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTGTAGTGAATAGAGTTAGGCAGGGATATTCACCATTA 2622 >623 TCGTTTCAGACCCACCTCCCAATCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGA 2691 1692 GAGAGAGACAGAGACAGATCCATTCGATTAGTGAACGGATCCTTAGCACTTATCTGGGACGATCTGCGG 2760 1761 AGCCTGTGCCTCTTCAGCTACCACCGCTTGAGAGACTTACTCTTGATTGTAACGAGGATTGIGGAACTT 2829 :830 CTGGGACGCAGGGGGTGGGAAGCCCTCAAATATTGGTGGAATCTCCTACAATATTGGAGTCAGGAGCTA 2898 899 AAGAATAGTGCTGTTAGCTTGCTCAATGCCACAGCTATAGCAGTAGCTGAGGGGACAGATAGGGTTATA 2967 968 GAAGTAGTACAAGAAGCTTATAGAGCTATTCGCCACATACCTAGAAGAATAAGACAGGGCTTGGAAAGG 3036 037 ATTTTGCTATAAGATGGGTGGCAAGTGGTCAAAAAGTAGTGTGGTTGGATGGCCTGCTGTAAGGGAAAG 3105 106 AATGAGACGAGCTGAGCCAGCAGCAGATGGGGTGGGAGCAGCATCTCGAGA 3156 FIGURE 2 (3 pages) 1 50
HXB-3 MRVKEK-----YQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATT BH-10
BH-8 F
LAV K I ARV-2 K - -GTRRN ----- - 51 100
HXB - 3 TLFCASDAKAYDTEVHNVWATHACVPTDPNPQEWLVNVTENFNMWKNDM BH-10 BH-8
LAV
ARV-2 R G N 101 150
HXB-3 VEQMHEDIISLWDQSLKPCVKLTPLCVSLKCTDLKNDTNTNSS-----SGRMIME BH-10 BH-8
LAV G A NTNSS E M ARV-2 Q T N G A NWKEEI------ 151 200
HXB-3 KGEIKNCSFNISTSIRGKVQKEYAFFYKLD11PIDND--TTSYTLTS---CNTSV BH-10
BH-8 K
LAV
ARV-2 T D I N L RN W AST N NYRLIH R 201 250
HXB-3 ITQACPKVSFEPIPIHYCAPAGFAILKCNNKTFNGTGPCTNVSTVQCTHG BH-10 BH-8
LAV A
ARV-2 T - K 251 300
HXB-3 IRPWSTQLLLNGSL AEEE WIRSVNFTDNAKTIIVQLNTSVEINCTRPN
BH-10 A Q
BH-8 D
LAV A Q
ARV-2 1 D N E A 301 350
HXB-3 NNTRKKIRIQRGPGRAFVTIGKIGNMRQ-AHCNISRAKWNATLKQIASKLR
BH-10 S N D
BH-8 D
LAV S
ARV-2 S Y -- Η T R IGDIRK Q N E VK 351 400
HXB-3 EQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTWFNSTW BH-10 BH-8
LAV
ARV-2 V N MR T N -RLNH 401 450
HXB-3 STEGSNNTEGSDTITLPCRIKQFINMWQEVGKAMYAP PISGQIRCS SNIT
BH-10 K I
BH-8 K I
LAV
ARV-2 - --- K N I I G S 451 500
HXB-3 GLLLTRDGG-NNNNGSEIFRPGGGDMRDNWRSELYKYKWKIEPLGVAPTK BH-10 -SE
BH-8 -SE
LAV
ARV-2 T VT DT V I I 501 550
HXB- 3 AKRRWQREKRAVGI-GALFLGFLGAAGSTMGAASMTLTVQARQLLSGIVQ BH-10 BH-8
LAV - R
ARV-2 VM V L 551 600
HXB- 3 QQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSG
BH-10 G BH-8
LAV
ARV-2 V R
DK177286A 1985-04-19 1986-04-17 AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin DK171119B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72502185A 1985-04-19 1985-04-19
US72502185 1985-04-19

Publications (3)

Publication Number Publication Date
DK177286D0 DK177286D0 (da) 1986-04-17
DK177286A true DK177286A (da) 1986-10-20
DK171119B1 DK171119B1 (da) 1996-06-17

Family

ID=24912812

Family Applications (1)

Application Number Title Priority Date Filing Date
DK177286A DK171119B1 (da) 1985-04-19 1986-04-17 AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin

Country Status (12)

Country Link
US (1) US6077935A (da)
EP (1) EP0199301B2 (da)
JP (1) JPS6212799A (da)
AT (1) ATE99330T1 (da)
AU (1) AU595511B2 (da)
CA (1) CA1341410C (da)
DE (1) DE3689447T2 (da)
DK (1) DK171119B1 (da)
ES (1) ES8706209A1 (da)
FI (1) FI861626A7 (da)
NO (1) NO861546L (da)
NZ (1) NZ215867A (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7205102B1 (en) 1983-09-15 2007-04-17 Institut Pasteur Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA
GB8423659D0 (en) 1984-09-19 1984-10-24 Pasteur Institut Cloned dna sequences
GB8429099D0 (en) 1984-11-16 1984-12-27 Pasteur Institut Closed dna sequences
US7232654B1 (en) 1983-09-15 2007-06-19 Institut Pasteur DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1)
US7351412B1 (en) 1983-12-05 2008-04-01 Institut Pasteur Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA
US5705612A (en) 1984-10-18 1998-01-06 Institut Pasteur And Centre National De La Recherche Scientifique NEF peptide encoded by human immunodefiency virus type 1 (HIV-1)
US7045130B1 (en) 1984-10-18 2006-05-16 Institut Pasteur Antibodies against antigens of human immunodeficiency virus (HIV-1)
US5980900A (en) * 1984-10-18 1999-11-09 Institut Pasteur And Centre National De La Recherche Scientifique Amino acid DNA sequences related to genomic RNA of human immunodeficiency virus (HIV-1)
US6894152B1 (en) 1984-11-16 2005-05-17 Institut Pasteur Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA
JPS62501263A (ja) * 1984-11-29 1987-05-21 スクリツプス　クリニツク　アンド　リサ−チ　フアウンデ−シヨン 脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体
IE64785B1 (en) * 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
FR2593519B1 (fr) * 1985-09-25 1994-01-07 Oncogen Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US4943627A (en) * 1986-06-12 1990-07-24 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US5017688A (en) * 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US5087557A (en) * 1986-06-23 1992-02-11 Genetic Systems Corporation Human monoclonal antibody to lymphadenopathy-associated virus
EP0525828A3 (en) * 1986-08-01 1993-02-24 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
US5166050A (en) * 1986-08-20 1992-11-24 Bristol-Myers Squibb Company Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
FR2610632B1 (fr) * 1987-02-11 1990-12-21 Pasteur Institut Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
EP0283327B1 (fr) * 1987-01-16 1997-06-25 Institut Pasteur Peptides ayant des propriétés immunologiques de HIV-2
US4861707A (en) * 1987-02-02 1989-08-29 E. I. Du Pont De Nemours And Company Human immunodeficiency virus antigen
CA1341277C (en) * 1987-03-16 2001-07-31 Roland Keith Mcgready Anti-paratopic antibody and a method of its manufacture
US4921787A (en) * 1987-05-01 1990-05-01 Cambridge Bioscience Corporation Detection of antibodies to human immunodeficiency virus by agglutination of antigen coated latex
FR2615623B1 (fr) * 1987-05-22 1992-06-19 Transgene Sa Test de diagnostic du sida base sur la mise en evidence d'une diversite de la reponse isotypique, vaccins et serotherapies
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
EP0602761A1 (en) * 1987-06-10 1994-06-22 The Immune Response Corporation, Inc. Prevention and treatment of retroviral disease
US5256767A (en) * 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
NO881501L (no) * 1987-10-09 1989-04-10 Repligen Corp Rekombinante htlv-111-proteiner og anvendelser av disse.
EP0311228A3 (en) * 1987-10-09 1990-05-02 Repligen Corporation Recombinant polypeptides and their uses, including assay for aids virus
US5254458A (en) * 1987-10-30 1993-10-19 Abbott Laboratories Immunoassays using antigens produced in heterologous organisms
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
EP0330359A3 (en) * 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
FR2640877A1 (da) * 1988-12-06 1990-06-29 Centre Nat Rech Scient
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
CA2358915C (en) * 1998-12-31 2010-06-01 Chiron Corporation Modified hiv env polypeptides
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP2412242A3 (en) 2001-07-05 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1427806A4 (en) 2001-08-31 2006-04-26 Chiron Corp ANTIGENIC HIV-TYPE B POLYPEPTIDE-CODING POLYNUCLEOTIDES, POLYPEPTIDES, AND USES THEREOF
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) * 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
DE2814039C3 (de) * 1978-03-31 1981-02-19 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), 3300 Braunschweig Verfahren zur Herstellung von Hybrid-Bakterien
US4743678A (en) * 1983-04-27 1988-05-10 President And Fellows Of Harvard College Method and products for detection of human T cell leukemia virus
JP2780020B2 (ja) * 1983-04-27 1998-07-23 プレジデント アンド フェロウズ オブ ハーバード カレッジ ヒトｔ細胞白血病ウイルス抗原及び該抗原を用いる検出方法
CA1341620C (en) * 1984-10-18 2011-08-23 Luc Montagnier Envelope antigens of hiv-1
EP0152030A3 (en) * 1984-02-03 1986-08-13 Juridical Foundation Japanese Foundation for Cancer Research Adult t cell leukemia virus antigen polypeptide
US4520113A (en) * 1984-04-23 1985-05-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US4725669A (en) * 1984-11-09 1988-02-16 President And Fellows Of Harvard College Assay for detecting infection by human T-cell lymphotropic virus-III
ATE138100T1 (de) * 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
IE64785B1 (en) * 1985-04-08 1995-09-06 Genetic Systems Corp Expression of immunologically reactive viral proteins
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease

Also Published As

Publication number Publication date
DE3689447D1 (de) 1994-02-10
FI861626A0 (fi) 1986-04-17
DE3689447T2 (de) 1994-04-28
EP0199301A1 (en) 1986-10-29
DK177286D0 (da) 1986-04-17
FI861626A7 (fi) 1986-10-20
ES554155A0 (es) 1987-06-01
US6077935A (en) 2000-06-20
ES8706209A1 (es) 1987-06-01
AU5636386A (en) 1986-10-23
NO861546L (no) 1986-10-20
CA1341410C (en) 2002-12-17
DK171119B1 (da) 1996-06-17
NZ215867A (en) 1989-10-27
AU595511B2 (en) 1990-04-05
ATE99330T1 (de) 1994-01-15
EP0199301B1 (en) 1993-12-29
JPS6212799A (ja) 1987-01-21
EP0199301B2 (en) 1997-07-09

Similar Documents

Publication Publication Date Title
DK177286A (da) Viruskappeprotein
Albert et al. A new human retrovirus isolate of West African origin (SBL-6669) and its relationship to HTLV-IV, LAV-II, and HTLV-IIIB
DK614987A (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
SE8701413D0 (sv) Expression and purification of an htlv-iii gag/env gene protein
ES8503951A1 (es) Un procedimiento para preparar un complejo inmunogenico que contiene proteinas o peptidos antigenicos
ES516620A0 (es) Procedimiento para producir interferon inmune humano.
NZ231850A (en) Structural and nonstructural feline infectious peritonitis virus (fipv) proteins and their preparation
ATE163013T1 (de) Alveolare oberflächenaktive proteine
ES8706208A1 (es) Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia
FI884823A7 (fi) Virusantigeeni, sen valmistusmenetelmä ja käyttö diagnoosissa ja hoido ssa
ATE109512T1 (de) Expression und diagnose mit gag-kodierten peptiden, die mit antikörpern gegen lav immunologisch reaktiv sind.
FI885296A0 (fi) Rekombinant hiv-2 polypeptid.
PT87375A (pt) Verfahren zur selektiven immunologischen bestimmung von intaktem prokollagen peptid (typ iii) und prokollagen (typ iii) in koeperfluessigkeiten und mittel zu dessen durchfuehrung
AU650649B2 (en) Human placenta angiogenic factor capable of stimulating capillary endothelial cell protease synthesis, DNA synthesis and migration
DK257887D0 (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
KR890008318A (ko) 플라스모듐 팔시파룸의 재조합 히스티딘-고함유 단백질, 이의 제조방법 및 용도
IT8349430A0 (it) Metodo per la produzione di proteine antigeniche specifiche del virusdell'epatite umana a, loro utilizzazione per la produzione di preparazioni farmaceutiche e mezzi diagnostici
ES8801959A1 (es) Un procedimiento para ensayos de sangre humana respecto de la presencia de anticuerpos frente al agente etiologico viral de sida

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired